Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant heteromultimeric neutralizing binding protein including two or multiple binding regions, such that the binding regions are not identical, and each binding region specifically binds a non-overlapping portion of the disease agent, thereby treating the subject for exposure to the disease agent. In a related embodiment, the heteromultimeric neutralizing binding protein includes two or multiple binding regions that neutralize a plurality of disease agents. In certain embodiments, the disease agent includes a bacterium, a bacterial protein, a virus, a viral protein, a cancer cell, and a protein or molecule produced therefrom. In certain embodiments, the disease agent is a plurality of different disease agents.
1. A composition comprising at least one recombinant heteromultimeric neutralizing binding protein comprising two or more specific binding regions and at least one epitope tag that is specifically bound by an antibody, wherein the binding regions are not identical and each of the binding regions specifically binds to a non-overlapping epitope of Clostridium difficile toxin A, and wherein the neutralizing binding protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 87 and SEQ ID NO: 95.
2. The composition of claim 1 , wherein the binding protein comprises a peptide linker that separates the specific binding regions.
3. A kit comprising the composition of claim 1 , a container, and instructions for use.
4. A composition comprising at least one recombinant neutralizing binding protein, wherein the binding protein comprises a recombinant camelid heavy chain-only VHH antibody of the amino acid sequence selected from the group consisting of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 87 and SEQ ID NO: 95.
5. A composition comprising at least one recombinant heteromultimeric neutralizing binding protein comprising two or more specific binding regions and at least one epitope tag that is specifically bound by an antibody, wherein the binding regions are not identical and each of the binding regions specifically binds to a non-overlapping epitope of Clostridium botulinum serotype A toxin, and wherein the neutralizing binding protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 56, SEQ ID NO: 57 and SEQ ID NO: 58.
6. The composition of claim 5 , wherein the binding protein comprises a peptide linker that separates the specific binding regions.
7. A kit comprising the composition of claim 5 , a container, and instructions for use.
8. A composition comprising at least one recombinant neutralizing binding protein, wherein the binding protein comprises a recombinant camelid heavy chain-only VHH antibody of the amino acid sequence selected from the group consisting of SEQ ID NO: 56, SEQ ID NO: 57 and SEQ ID NO: 58.
9. A composition comprising an isolated recombinant polypeptide comprising an amino acid sequence that is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 87 and SEQ ID NO: 95.
10. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 56.
11. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 57.
12. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 58.
13. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 59.
14. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 60.
15. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 61.
16. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 62.
17. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 63.
18. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 64.
19. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 87.
20. The composition of claim 9 , wherein the amino acid sequence is at least 97% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 95.